Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Criteria Clinicians Use to Classify Patients as High Risk in Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer.

Advances in therapy·2026
Same author

Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice.

Future oncology (London, England)·2026
Same author

Family perspective: raising a child with NEC and the need for multidisciplinary care.

World journal of pediatric surgery·2026
Same author

Developing and validating a sequence-aware deep learning model for infection risk prediction in home care.

International journal of medical informatics·2026
Same author

Marital status and post-radical prostatectomy outcomes: results from the SEARCH database.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Diet in Prostate Cancer: Promising Side Dish or Main Course?

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study.

Advances in therapy·2026
Same journal

Peripheral and Autonomic Diabetic Neuropathy and Their Additive Risk of Major Adverse Liver Outcomes in Type 2 Diabetes.

Advances in therapy·2026
Same journal

Diagnostic Delay in Multiple Sclerosis in China: A Nationwide Cross-Sectional Study.

Advances in therapy·2026
Same journal

Treating Severe Obesity: A Medical Perspective.

Advances in therapy·2026
Same journal

Correction: Transition Care for Young People with Rare Bone and Mineral Conditions: A Scoping Review.

Advances in therapy·2026
See all related articles
  1. Home
  3. Real-world Treatment Patterns For Patients With High-risk Biochemically Recurrent Nonmetastatic Castration‑sensitive Prostate Cancer.
  1. Home
  3. Real-world Treatment Patterns For Patients With High-risk Biochemically Recurrent Nonmetastatic Castration‑sensitive Prostate Cancer.

Related Experiment Video

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration‑Sensitive

Stephen J Freedland1,2, Amanda Ribbands3, David Russell4

  • 1Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars‑Sinai Medical Center, 8635 West 3rd Street, 1070W, Los Angeles, CA, 90048, USA. Stephen.Freedland@cshs.org.

Advances in Therapy
|June 1, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Patients with high-risk prostate cancer receive prompt treatment following diagnosis, with guideline adherence being the primary driver for treatment selection. This real-world data supports early intervention strategies for biochemical recurrence.

Keywords:
Cross-sectional studiesProstate-specific antigenProstatic neoplasmRecurrenceTherapeutics

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Related Experiment Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Area of Science:

  • Oncology
  • Urology
  • Clinical Research

Background:

  • Recent phase 3 trials and guidelines advocate for early, aggressive treatment in high-risk biochemically recurrent nonmetastatic castration-sensitive prostate cancer.
  • Real-world treatment patterns for this patient population require assessment to ensure alignment with recommended guidelines.

Purpose of the Study:

  • To evaluate current real-world treatment practices for patients diagnosed with high-risk biochemically recurrent nonmetastatic castration-sensitive prostate cancer.
  • To determine the alignment of these practices with established clinical guidelines.

Main Methods:

  • A retrospective, cross-sectional survey was conducted with US urologists and radiation oncologists between April and November 2023.
  • Data were collected via physician responses on treatment perspectives and patient record forms for 535 patients with high-risk biochemical recurrence.
  • Descriptive analyses were performed on the collected data.

    • Main Results:

    • The median time from diagnosis of high-risk biochemical recurrence to first-line treatment was 20 days.
    • The most frequent first-line treatments included androgen deprivation therapy alone (28%), radiation (20%), and androgen receptor pathway inhibitor plus androgen deprivation therapy (19%).
    • Physician adherence to treatment guidelines was the most cited reason (49%) for selecting first-line therapy.

    Conclusions:

    • Real-world clinical practice shows prompt initiation of first-line treatment for patients with high-risk biochemically recurrent prostate cancer.
    • Adherence to clinical guidelines is a primary factor influencing treatment decisions in this patient cohort.
    • These findings support the clinical benefit of early intervention for prostate cancer biochemical recurrence.